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Abstract 
 
Greko, C. 2003. Tissue cages in calves for studies on pharmacokinetic/pharmacodynamic 
relationships of antimicrobials. Doctor’s dissertation 
ISSN 1401-6257, ISBN 91-567-6373-4 
 
Knowledge on pharmacokinetic/pharmacodynamic (PK/PD) relationships of antimicrobials 
may assist in defining a dose that maximises effect while minimising side effects such as 
selection of resistance. The aim of this thesis was to develop a model for studies of PK/PD 
relationships of antimicrobials in presence of the host defences. To this end, the usefulness 
of subcutaneously implanted tissue cages was explored.  
Tissue cages implanted in calves were infected with Escherichia coli and the calves were 
treated iv with different doses of trimethoprim + sulfadoxine. Irrespective of dose, no effect 
was noted in cages infected before treatment. In vitro studies and analysis of thymidine 
indicate that the effect of trimethoprim was antagonised by thymidine in tissue cage fluid.  
When the antimicrobial is administered systemically as above, the pharmacokinetics of 
the drug in tissue cage fluid is typically sluggish. It was shown that if tissue cages with a 
constant diffusion area but different volumes are used, and drug is injected directly into the 
cages, the volume of the cage will determine the elimination rate of the drug. Thereby, by 
varying the dose and cage-type, a range of concentration-time profiles can be simulated. 
To explore the utility of this concept, the effects of penicillin and danofloxacin against 
infections with Mannheimia haemolytica in tissue cages in calves were studied. For 
penicillin, the area under the curve to minimum inhibitory concentration (MIC) and time 
above MIC were equally predictive for effect. For danofloxacin, the area under the curve to 
MIC predicted the effect, and the magnitude needed for near maximum effect was 240-244 h. 
These results are in line with information for other fluoroquinolone-bacterial combinations. 
The advantage of the described model is that different concentration-time profiles can be 
simulated, and concentrations of drug at the site of infection and bacterial counts can be 
monitored over time in presence of the host defences. Its validity needs to be challenged by 
direct comparisons with other models, and by clinical studies. The results suggest it can be 
a useful intermediary step between in vitro studies and clinical trials aiming at drug dosage 
optimisation.  
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Abbreviations 
 
AUBC  area under the bacterial counts – time curve (log cfu/mL × h) 
AUC  area under the antimicrobial concentration - time curve (mg/L × h) 
cfu  colony forming units (of bacteria) 
∆cfumax  maximum difference in colony forming units per volume from 
time 0 (log cfu/mL) 
Cmax  maximum drug concentration (mg/L; µg/ml) 
Emax model  non-linear mathematical model with a minimum and maximum 
effect level (a dose-response model) 
IE  intensity of effect; measure of antibacterial effect defined as the 
area between bacterial kill curve including regrowth and growth 
control curve (log cfu/mL × h) 
Kel  elimintation rate constant 
MBC  mimimum bactericidal concentration (of an antimicrobial) (mg/L; 
µg/ml) 
MHB Mueller–Hinton  Broth 
MIC  minimum inhibitory concentration (of an antimicrobial) (mg/L; 
µg/ml); note: free concentration of drug  
MICtot  minimum total concentration needed for inhibiton of growth; i.e. 
including both free and protein bound drug (mg/L; µg/ml) 
PAE  post antibiotic effect 
PD pharmacodynamics 
PK pharmacokinetics 
PME  post MIC effect 
SA surface-area 
t time  (h) 
t1/2  half-life of drug (h) 
T>MIC  the time concentrations remain above MIC (% or h) 
TCF  tissue cage fluid 
V volume  
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Background 
 
Fifty years ago, Eagle, Fleichman & Levy (1953) concluded a report on the effect 
of different dosage intervals of penicillin on therapeutic efficacy with the 
following paragraph: 
 
‘The data here reported, and the conclusions drawn from them, apply solely to penicillin. 
With this antibiotic there is a maximally effective concentration, varying from strain to 
strain, that kills the organisms at the fastest possible rate, and even a ten-thousandfold 
increase in penicillin concentration beyond this maximally effective level does not further 
accelerate its bactericidal action. The time-dosage relations discussed above follow directly 
from this property. With the other antibiotics, the bactericidal effect either increases 
continuously with the concentration used (as with streptomycin and bacitracin) or is so slow 
(as with aureomycin, chloramphenicol and terramycin) as to suggest that host factors 
contribute materially to their therapeutic effect. With streptomycin and bacitracin, the most 
rapidly effective schedule would, a priori, be one providing the maximum concentration, 
and for the longest continuous period, consistent with the toxicity of the drug. With the 
latter group of antibiotics the time-dosage relations remain to be determined. Studies on the 
degree to which the host contributes to their therapeutic action, and the nature of the host 
effect, are clearly pertinent in this connection.’ 
 
Since, the knowledge in this area has increased considerably. The essence of the 
statement regarding the degree of concentration dependency of different groups of 
antimicrobials and implications thereof, however, still holds true. The questions 
discussed in the citation are crucial for antimicrobial therapy: what is the optimal 
dose and what is the optimal dosage interval? 
 
Pharmacokinetics and pharmacodynamics 
The effect of an antimicrobial treatment is the result of a dynamic three-way 
interaction between the host, the drug, and the infecting organism. 
Pharmacokinetics (PK) is what the host does to a drug, i.e. absorption, 
distribution, metabolism and elimination, as reflected in the time course of drug 
concentrations in plasma or tissue. Pharmacodynamics (PD) is the effect of the 
drug as a function of its concentration. For antimicrobials, the effect is often 
measured as killing or inhibition of bacteria, but it should be stressed that this is 
the result of the drug’s interaction with receptors in or on the bacterial cell. The 
study of PK/PD relationships links the concentration-time profile resulting from 
pharmacokinetics to the effect of these concentrations on bacteria. Such studies 
may, or may not, include the third component of interest, the interaction between 
the host and the pathogen.  
 
Defining the optimal dose 
Many of the currently used dosage regimens of antimicrobials are designed to 
maintain serum levels above the minimum concentration needed to inhibit growth 
of the target pathogen for the greatest possible proportion of the dosing interval 
(CPMP, 2000; Lees & Aliabadi, 2002). For penicillin, this is in line with the 
findings of Eagle, Fleichman & Levy (1953), but for other antimicrobials it  
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ignores the condition stressed by the authors; different strategies should apply for 
different classes of antimicrobials.  
 
This early insight has been reinforced by knowledge gained in the last decades 
on how relevant PK/PD relationships are for dose setting. Even if clinical trials 
and experience show that a certain dose leads to a high degree of clinical success, 
this does not automatically mean that the efficacy of the antimicrobial is fully 
exploited. It may be that another dose or dosage interval would lead to an even 
higher probability of success (clinical or microbiological), or reduce the risk of 
adverse effects. Certain dosages of antimicrobials may also increase the risk for 
selection of resistant bacteria. The importance of optimised antimicrobial therapy 
has therefore been further emphasised by the need to contain the global increase in 
resistance among bacteria (WHO, 2001).  
 
Ideally, dose-ranging studies should define the minimum and the maximum 
effective dose and dose interval. For this, the responses to a variety of doses, 
ranging from sub-optimal to potentially toxic regimens should be compared 
(Toutain, del Castillo & Bousquet-Mélou, 2002). It is, however, economically 
unrealistic and unethical to fully explore this in clinical trials.  
 
Studies on PK/PD relationships of antimicrobials by use of in vitro or animal 
models, or both, may assist in defining the pharmacokinetic parameter that best 
predicts the effect on specific target organisms, and its critical levels. For example, 
identification of the ratio of peak concentration and MIC as outcome predictor for 
aminoglycosides (e.g. Moore, Smith & Lietman, 1984) led to a shift from twice 
daily to once daily dosing for humans (Craig, 1998) and in veterinary medicine 
(Prescott, Baggot & Walker, 2000). There is also evidence that the likelihood of 
selection of bacteria with mutations conferring resistance can be predicted on basis 
of PK/PD relationships (e.g. Blaser et al., 1987; Madaras-Kelly et al., 1996; Hyatt 
& Schentag, 2000).  
 
The optimal dose and dosage interval should maximise effect while minimising 
the risk for adverse effects such as resistance, toxicity and, for food-producing 
animals, residues in edible products. Knowledge of different aspects of PK/PD 
interactions, and of variability within the populations concerned (hosts and target 
bacteria), can assist the identification of a dose and schedule that has a high 
likelihood of meeting the criteria for optimum (Drusano et al., 2001). With such 
an approach, currently used dosages may be challenged. For new drugs, a rational 
framework for selection of doses to be evaluated in clinical trials is provided.  
 
Basic pharmacodynamic concepts 
MIC and MBC 
The simplest and most widely used measure of the intrinsic activity of 
antimicrobials is the minimum inhibitory concentration (MIC). Its determination is 
usually straightforward; bacteria are exposed to two-fold dilutions of the 
antimicrobial in broth or agar and, after incubation, the lowest concentration that 
inhibits visible growth is recorded as the MIC (NCCLS, 1997; EUCAST, 2000). 
The minimum bactericidal concentration (MBC) is defined as the concentration  
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that kills 99.9% of the initial inoculum (NCCLS, 1999; EUCAST, 2000). The 
MIC is influenced by factors such as density of the inoculum, medium, incubation 
temperature and time, etc. Therefore, the use of standardised protocols is 
imperative (e.g. White et al., 2001). 
 
The relevance of MICs for the in vivo situation has always been questioned. The 
standardised conditions of the test (e.g. defined inoculum size, artificial media and 
static concentrations) are truly different from those expected at the site of 
infection. Nonetheless, clinical and experimental evidence indicate a good 
correlation between MICs and effect (e.g. Schentag, 1991; Craig, 1993; Knudsen, 
Frimodt-Moller & Espersen, 1995; Preston et al., 1998).  
 
The MIC assumes a pivotal role when it is used to correlate pharmacokinetic 
parameters to potency, i.e. to calculate the PK/PD indices time above MIC (T>MIC), 
area under the drug concentration-time curve to MIC (AUC/MIC) and peak 
concentration to MIC (Cmax/MIC) (see below). Two important caveats relating to 
this must be stressed. First, MICs are generally determined by use of two-fold 
dilutions of the drug. The true MIC is mostly not the figure determined, but in 
between the observed MIC and the next lower dilution. The inherent error is one 
dilution step in either direction. Evidently, this imprecision may have a profound 
influence for the calculated PK/PD indices (Frimodt-Moller, 2002).  
 
The second caveat relates to the use of MIC90 (i.e. the 90
th percentile of the 
MICs in a given material) as denominator to account for variation in MICs in a 
particular bacterial species. The MICs of a given drug for strains in a population of 
bacteria where resistance has emerged often assumes a bimodal distribution. In 
such cases, the MIC90  will increase in a stepwise manner. For example, for 
Staphylococcus intermedius, an increase in the proportion of erythromycin 
resistant isolates from 9 to 10% would mean an increase of the MIC90 from 1 (or 
less) to more than 8 mg/L [theoretical example based on MIC distributions given 
in SVARM 2001 (2002)].  Still, in most cases there would be no true difference in 
the sampled bacterial population. From this follows that if the MIC90, or the MIC50 
(the median value), is used for PK/PD integration, only the wild (inherently 
susceptible), part of the population should be considered whenever there is a 
bimodal distribution (CVMP, 2002). 
 
Notwithstanding, the MIC is still a reasonable approximate of the concentration 
of free drug needed at the site of infection. Prediction of effect based on 
pharmacokinetic parameters is improved if they are correlated to the MIC of the 
infecting strain (e.g. Drusano et al., 1984; Leggett et al., 1989; Schentag, Nix & 
Adelman, 1991; Preston et al., 1998).  
 
Time-kill curves 
Bacterial time-kill curves are a simple and informative way to obtain basic 
information on the kinetics of the effect of an antimicrobial. The methodology is 
similar to the MBC determination procedures; bacteria are exposed to various 
static concentrations of the antimicrobial, and viable counts are performed at the 
start and at various times after inoculation (NCCLS, 1999; EUCAST, 2000). From 
such curves, it can be deduced whether the rate of killing increases with increasing  
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concentrations, or if the influence of increasing concentrations is marginal above 
low multiples of the MIC. For a third category, the bacteriostatic drugs, almost no 
killing is observed.  
 
The concentrations of the antimicrobial in traditional time-kill curve 
experiments are static, and represent a situation at steady state. Models with 
variable drug concentrations are an extension of the time-kill curve methodology 
(see ‘Experimental models for PK/PD studies’).  
 
Sub-inhibitory concentrations and post antibiotic effects 
The MIC is, as defined above, the lowest concentration that inhibits growth but 
exposure of a bacterium to lower (sub-MIC) concentrations may result in a variety 
of effects, such as reduced growth rate, and altered morphology, ultrastructure, 
antigenicity, adherence, and toxin production (Lorian, 1993).  
 
After exposure to concentrations above MIC a delay in regrowth can often be 
observed, even if the drug is completely removed. Various types of effects have 
been studied in this respect (for a review see Odenholt, 2001). Of these, the in 
vitro measure post-MIC effect (PME) and the corresponding in vivo post antibiotic 
effect (in vivo PAE), are probably the most clinically relevant (den Hollander et 
al., 1998a; Odenholt, 2001). Both PME and in vivo PAE are defined as the time it 
takes for a culture to increase 1 log cfu/ml from the time when the concentrations 
of an antimicrobial have declined below MIC, i.e. the inhibition of regrowth 
(Mouton et al., 2002). These effects will most likely be influenced by the time it 
takes for bacteria to repair sublethal damage caused at supra-MIC concentrations, 
but above all by sub-MIC effects (Löwdin et al., 1996; den Hollander et al., 
1998a). 
 
Drug concentrations of concern 
Antimicrobials will bind to different degrees to proteins and other molecules in 
plasma or other body fluids to different degrees. Only the free (non-bound) 
fraction of the drug can interact with bacterial receptors (e.g. Rolinson, 1980; 
Odenholt, Holm & Cars, 1987; Garrison et al., 1990). Therefore, it is only the 
concentration of free drug that is of concern for its PK/PD relationship.  
 
When a drug is administered, it is first absorbed to the blood (unless given i.v.), 
then distributed into tissue. Ideally, the concentration of free drug in the 
extracellular space at the site of infection should be determined and related to 
effect (Liu, Muller & Derendorf, 2002). For tissues where there is no barrier to 
penetration, the level of free drug in serum is an adequate surrogate marker for 
these concentrations (Cars, 1991).  
 
In veterinary medicine, total tissue concentrations are still frequently reported 
with the argument that high ‘tissue levels’ means superior antibacterial activity. 
This may be grossly misleading (Toutain, del Castillo & Bousquet-Mélou, 2002). 
Such total concentrations are mostly determined from homogenates of tissue, and 
represent a mean of concentrations of drug within and outside cells and in 
capillaries. About 80% of the volume of tissue is the intracellular space, and  
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therefore total tissue concentrations will largely reflect the degree of drug 
distribution into cells (Nix et al., 1991). Most infections of interest are, however, 
located extracellularly and direct comparisons of total tissue concentrations with 
pharmacodynamic parameters are therefore meaningless (Cars, 1991).  
 
PK/PD relationships – methodological aspects 
Most studies on PK/PD relationships of antimicrobials are essentially designed to 
explain how the concentration-time profile of a drug relates to the magnitude and 
time course of effect on bacteria. The crux of the matter is how to assess the 
relation between one dynamic event and another. In the in vivo situation, this is 
further complicated by the fact that a third factor, the host, also influences 
outcome in a dynamic way. To simplify, the concentration-time curve of the drug 
is mostly ‘reduced’ to pharmacokinetic parameters, correlated to a relevant MIC 
and used as PK/PD indices. Likewise, the bacterial kill-curve can be expressed as 
different measures of effect.  
 
The PK/PD field has evolved rapidly over the last two decades and a number of 
different definitions and expressions have been coined. Recently, a proposal of a 
standardised PK/PD terminology has been presented (Mouton et al., 2002) by 
which some of the confusion in the area will hopefully be resolved.  
 
PK/PD indices 
The three PK/PD indices commonly used reflect different aspects of the 
concentration-time curve; the time (T>MIC), the peak of the curve (Cmax/MIC), and 
the integrate of time and concentrations calculated as area under the curve 
(AUC/MIC) (Figure 1). These indices will co-vary to a large extent. For example, 
with a given rate of elimination of a drug, and a fixed dosing interval, any increase 
in Cmax will also increase the AUC and the T>MIC. With a dose escalation and 
fractionation design, the co-linearity of the indices can be reduced.  
 
 
 
Figure 1. Illustration of the 
pharmacokinetic parameters that 
form the basis of common 
PK/PD indices, and of time 
above MIC (based on data from 
Bengtsson  et al., 1989; 
concentration-time profile of 
penicillin G after intramuscular 
injection; data from one calf). 
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Time of exposure 
For antimicrobials showing minimal concentration-dependency (e.g. pencillins, 
cephalosporins), the time of exposure (T>MIC) will determine the effect. The T>MIC 
is defined as the percentage of a 24 h period that the free concentration of drug 
exceeds MIC (Mouton et al., 2002), but is also frequently expressed as the 
chronological time (h) (Frimodt-Moller, 2002). For drugs with these 
characteristics, frequent dosing or a slow release formulation may be considered, 
but little will be gained by increasing the doses. 
 
The applicability of T>MIC for sustained release (long acting) formulations with 
dosing intervals of 48 h or more must be questioned. In those cases, then T>MIC is 
50% the concentrations will be below MIC for 24 h or more. It is probable that 
this time is sufficient for regrowth to occur. For prediction of dosages of this type 
of formulations, identification of a maximum time in h below MIC might be of 
interest. 
 
Degree of exposure  
The effect of concentration dependent antimicrobials (e.g. aminoglycosides, 
fluoroquinolones) will depend on the degree of exposure, i.e. the concentrations in 
relation to MIC. The PK/PD indices of interest are Cmax/MIC and AUC/MIC. The 
Cmax/MIC is the ratio between the highest concentration of free drug reached in the 
compartment of interest and the MIC (Mouton et al., 2002). The AUC/MIC is 
normally determined from the AUC over 24 h. When other time periods are used, 
this should be indicated by a subscript (Mouton et al., 2002). The dimension of 
AUC/MIC is time (h), and it reflects the total exposure. For drugs that depend on 
Cmax/MIC for effect, infrequent large doses are probably best, and for those who 
depend on AUC/MIC various approaches may be equally effective. A high 
Cmax/MIC or a large AUC/MIC is probably needed to prevent selection of resistant 
mutants (Woodnutt, 2000). 
 
The expression AUIC (area under the inhibitory curve) was originally used for 
the area under curve of the reciprocal serum inhibitory titres versus time (Flaherty 
et al., 1988). The serum inhibitory titre is determined as the highest titre of the 
sample that inhibits growth of a chosen bacterial strain (NCCLS, 1999; EUCAST, 
2000). The acronym AUIC is sometimes used to designate the AUC above MIC 
(AUC>MIC), or as a synonym to AUC/MIC. While these three indices are 
conceptually similar, they are not identical, and it has been recommended that 
AUIC should be reserved for its original definition (Mouton et al., 2002).  
 
There is some controversy as to which of Cmax/MIC and AUC/MIC that best 
predicts the effect of, e.g., the fluoroquinolones. Discrimination between these two 
indices is difficult because of their inherent co-linearity. Further, it is possible that 
they interact. For example, in a study by Drusano et al. (Drusano et al., 1993) the 
Cmax/MIC of fluoroquinolones was best linked to survival when this index was 
above 10, while AUC/MIC was a better predictor when Cmax/MIC was below 10. 
Further, in a study by MacGowan et al (MacGowan et al., 2001), the initial slope 
of the bacterial kill-curve (rate of bacterial kill) was predicted by Cmax/MIC, while 
the overall effect was predicted by AUC/MIC.  
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Outcome parameters, endpoints, or measures or antibacterial effect 
The outcome of an antibacterial treatment can be measured clinically (success, 
survival, specific criteria) or microbiologically (eradication of bacteria, decrease in 
bacterial density). Lately, emergence, or non-emergence, of resistance has been 
added to the list. The conclusions in a particular study reached will, to some 
extent, be tied to the chosen measure of effect.  
 
Most experimental models, and some types of clinical studies, allow for 
sampling at least before and after treatment. In these cases, the antibacterial effect 
can be measured directly. Depending on the study design and possibilities of 
repeated sampling, three different categories of measures may be considered; 
changes in bacterial counts, time-to-kill and integrated measures reflecting both 
bacterial counts and time (MacGowan & Bowker, 2002). For an illustration, see 
Figure 2. 
 
Figure 2. Illustration of measures 
of antibacterial effect. AUBC is the 
area under bacterial kill curve 
(dotted area), IE is the area between 
kill-curve and control until 
regrowth, slope of kill from 0 to 24 
h is shown as straight broken line 
[Data are means of viable counts of 
M.  haemolytica  in non-treated 
tissue cages (broken line) and small 
cages treated with high dose 
penicillin G (solid line);  data from 
study III)]. 
 
Change in bacterial counts 
The simplest measures of effect reflect the change in bacterial counts from the 
start of the experiment to a predefined time-point, generally the end of the last 
dosing interval. When repeated sampling is possible, the maximum reduction in 
colony forming units (∆cfumax) can also be defined.  
 
Point-measures have the merit of being easy to understand, and are mostly easy 
to determine. However, they depend on one single measurement and are therefore 
sensitive to analytical errors (MacGowan et al., 2000). A further disadvantage is 
that they do not fully reflect the effect before or after the predefined point, which 
negatively affects their discriminatory power (Firsov et al., 1997; Firsov et al., 
1998; MacGowan et al., 2000). 
 
Time to event 
Another group of frequently used measures is time-to kill measures. Generally 90, 
99 or 99.9% reduction of the initial bacterial counts, i.e. a decrease by 1, 2 or 3 log 
cfu, is used (MacGowan, Rogers & Bowker, 2000). These measures reflect the 
speed of initial kill, and will probably for concentration-dependent antimicrobials, 
such as fluoroquinolones, depend on the peak concentrations of the antimicrobial 
(MacGowan et al., 2001). The time to event measures will to varying degrees  
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depend on the chosen sampling scheme, as the lowest possible value will be the 
first sampling time. If killing is more rapid kill at higher concentrations, that will 
go unnoticed. Further, these measures do not reflect changes after the predefined 
event. 
 
Bacterial counts and time 
The use of measures integrating bacterial counts and time requires a study design 
that allows for repeated measurement of effect. Measures such as the slope of, or 
area below, or above, the kill curve are less dependent on individual time-points 
and are thereby more robust (MacGowan et al., 2000). The area under the kill-
curve to different arbitrarily chosen time-points, AUBCt, is by far the most widely 
used variant. Another area measure is the intensity of effect, IE, defined by Firsov 
et al. (e.g. Firsov et al., 1997) as the area between the kill-curve and the control 
curve until complete regrowth.  
 
The IE will depend on the time it takes for bacteria to start regrowth. This in turn 
depends on the time during which inhibitory concentrations are maintained in the 
system (T>MIC) plus any post-antibiotic effect, and IE will thus be influenced by the 
t1/2  of the antimicrobial (MacGowan, Rogers & Bowker, 2000). By contrast, 
AUBCt  where time is the end of the last dosing interval will for, e.g. 
fluoroquinolones, depend mainly on AUC/MIC (MacGowan & Bowker, 2002).  
 
In addition to better reproducibility compared with point-measures, integrated 
measures have the advantage that they always provide a numerical value to the 
endpoint, while changes in bacterial counts and time-to-kill are unchanged once a 
maximum is reached (i.e. eradication). Disadvantages are the need for repeated 
sampling and culture, and that area measures are less easy to understand and relate 
to the clinical situation (MacGowan & Bowker, 2002).  
 
Analysis of data 
Methods for relating the drug concentration-time curve to the bacterial kill curve 
range from entirely descriptive to the use of mathematical PK/PD models. 
Common objectives for the analysis are to define the PK/PD index that best 
predicts the effect, and the magnitude of that index that results in a certain degree 
of effect.  
 
It is likely that, if studied over a sufficient range, the relation of the predictive 
index to effect is non-linear: At very low exposures, there is no effect. At higher 
exposures, the effect increases with dose but there is a biological maximum (i.e. 
total eradication of the target bacteria) and when this is reached there is no further 
benefit in increasing the exposure. Non-linear models used to describe such 
relations are based on the Hill equation and are often referred to as sigmoid Emax 
models (Holford & Sheiner, 1981). However, there are no easy ways to 
objectively compare the fit of a non-linear model to different data combinations 
and such models are not suited to discriminate between the predictive power of 
different PK/PD indices. Therefore, techniques based on linear regression are 
commonly employed as a first step. An Emax model may then be used to describe 
the relation between the most predictive index and outcome, and to estimate the  
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magnitude of the index producing a specified percentage of the maximum effect 
can be estimated.  
 
As mentioned above, the indices and effect parameters are simplifications of the 
two curves. More elaborate PK/PD models that truly link the dynamic events 
would probably be more informative. Such models will, be limited by the 
assumptions underlying the model (CPMP, 2000). Hitherto, this approach has 
received limited attention. The utility of models of varying complexity has been 
explored (Zhi, Nightingale & Quintiliani, 1986; Zhi, Nightingale & Quintiliani, 
1988; Mattie et al., 1990; Hishikawa et al., 1991; Li, Nix & Schentag, 1994; 
Renard et al., 1996; Mattie et al., 1997; Mouton, Vinks & Punt, 1997; Corvaisier 
et al., 1998; Yano et al., 1998). A further expansion of this area could increase the 
understanding of the dynamics of the interactions, leading to more refined 
predictions based on experimental data. 
 
Experimental models for PK/PD studies 
Most current knowledge of the PK/PD relationship of antimicrobials derives from 
a variety of in vitro and animal models.  
 
In vitro models  
In  in vitro kinetic models, dilution or diffusion (through dialysis) is used to 
simulate the clearance of drug from the system (the body) (e.g. Grasso et al., 1978; 
Zinner, Husson & Klastersky, 1980; Toothaker, Welling & Craig, 1982). Disease 
specific models using fibrin clots or glass beads to simulate endocarditis or device 
related infections, respectively, have also been described (e.g. Vergères & Blaser, 
1992; McGrath, Kang & Kaatz, 1994). These in vitro kinetic models allow for 
experiments on the effect of different defined concentration-time profiles of a drug 
on selected bacterial strains in a controlled and reproducible environment. 
(MacGowan, Rogers & Bowker, 2000). Different aspects of PK/PD relationships, 
including selection of resistance, can be studied and critical factors identified.  
 
Results obtained in these models are affected by the same factors as MIC 
determinations, e.g. medium, growth phase of inoculum and its density. Further, 
model specific factors such as dilution effects and presence of sessile (adherent) 
bacteria may influence outcomes. Such factors, coupled with varying study 
designs and analytical procedures probably explain the conflicting results that are 
sometimes reported (MacGowan, Rogers & Bowker, 2000). Nonetheless, a 
significant amount of knowledge has been generated through use of in vitro 
models (for a review see MacGowan & Bowker, 2002). A limited number of 
studies using such models deal specifically with antimicrobial-pathogen 
combinations of veterinary interest (Koritz, Kilroy & Bevill, 1994; Lindencrona, 
Friis & Jensen, 1999; Lindencrona, Friis & Aarestrup, 2000).  
 
These models are flexible, reproducible and relatively low cost. Thereby, they 
are excellent tools for studies on most aspects of PK/PD relationships of 
antimicrobials. They do not, however, account for effects of the interaction 
between the host and the infecting organism.  
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Experimental infections in small rodents 
Experimental infections in animals have been used extensively to study the 
pathogenesis of infections. A variety of infection models in small rodents (mice, 
rats, rabbits or guinea pigs) have also been developed for studies on the 
pharmacodynamics of antimicrobials (Zak & O'Reilly, 1991; Andes & Craig, 
2002a). These models are either general (thigh infections, peritonitis-septicemia) 
or reflect more specific disease conditions (pneumonia, meningitis, endocarditis, 
pyelonephritis, abscesses, foreign-body infections etc). Each model has its own 
limitations, but there are also more general factors that affect the conclusions, such 
as choice of bacterial strains, inoculum size, time between infection and treatment 
and dosing regimen (Cleeland & Squires, 1991).  
 
The main shortcoming of these models is the difference in pharmacokinetics 
between small rodents and man, or larger animals. This may, to some extent, be 
overcome through dose fractionation or prolongation of the elimination rate 
through, e.g., renal impairment (Zak & O'Reilly, 1991; Andes & Craig, 2002a). 
Some other factors are also of concern regarding extrapolation of results to the 
clinical situation. Treatment is often initiated soon after infection and it has been 
questioned whether results are representative of therapy of established infections 
(Barza, 1978; Zak & O'Reilly, 1991). Further, the animals are often rendered 
neutropenic before infection, which nullifies the effect of the host defences. 
Finally, the measures of effect used range from bacterial counts over time to 
survival, depending on the possibilities of repeated sampling. This may in turn 
may influence the conclusions (Hyatt et al., 1995). 
 
As for the in vitro models, conflicting results are probably to a large extent 
explained by factors discussed above. Still, studies designed specifically to 
compare results from different animal models (Erlendsdottir et al., 2001), or from 
an in vitro and an animal model (Blaser et al., 1995; den Hollander et al., 1998b; 
Bonapace et al., 2002) indicate that the results from the different models agree on 
a general level. The relatively few clinical studies (in man) on PK/PD 
relationships and dose optimisation also confirm the general findings from both in 
vitro and animal models (for a review see Frimodt-Moller, 2002).  
 
Most research relating to PK/PD relationships of antimicrobials in small rodent 
models has been focused on antimicrobial therapy of man. One example of a 
veterinary application of a model in small rodents is a series of studies relating 
results from a thigh infection model in guinea pigs to pharmacokinetic profiles of 
different drugs in dogs (Meinen, McClure & Rosin, 1995; Campbell, Bartholow & 
Rosin, 1996; McClure & Rosin, 1998). Still, conclusions valid for human 
medicine should to a large extent be valid also for veterinary medicine as the 
target for the drug is bacteria and not the host.  
 
Models in larger animals, with emphasis on tissue cages 
In veterinary medicine, dose-titration studies can often be performed in models of 
infection in the animal species of direct interest (e.g. Yancey et al., 1990; Hibbard 
et al., 2002). Mostly, the results are only presented in terms of effect versus dose. 
Analysis of data in studies relating pharmacokinetic parameters to effect directly  
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in the animal host of concern range from descriptive (e.g. White, Piercy & Gibbs, 
1981; Franklin et al., 1984; Sarasola et al., 2002) to mathematical modeling of 
results (Renard et al., 1996). One experimental model that has attracted some 
attention for pharmacodynamic studies is the tissue cage model (Clarke, 1989).  
 
Tissue cages are perforated hollow devices, mostly implanted subcutanelously. 
After implantation, the cages fill up with a fluid with about half the protein content 
of serum (Bengtsson, Luthman & Jacobsson, 1984). Such models have been used 
extensively for studies on pharmacokinetics of antimicrobials in animal species of 
direct veterinary interest (for a review see Clarke, 1989). Their clinical counterpart 
has, however, not been clearly defined (Bengtsson, 1990).  
 
Tissue cages can also be used to contain an infection, and can thereby be used to 
study the pharmacodynamics of antimicrobials. Most studies have been conducted 
in small rodents (Rylander et al., 1981). The cage in itself represents a foreign-
body, and this type of model has been used to study various aspects of device 
related infections (for a review see Zimmerli, 1993).  
 
The pharmacodynamics of different antimicrobial-pathogen combinations has 
also been studied in tissue cage models in calves, dogs, and horses (e.g. Powers, 
Varma & Powers, 1984; Wagner et al., 1986; Beadle et al., 1989; Clarke et al., 
1989c; McDevitt et al., 1992; Ensink et al., 1996a; Gruet, Richard & Autefage, 
1997). The measured effects have generally been related to drug concentrations at 
the site of infection in a descriptive way. Lately, this type of model has also been 
used for more explicit studies of PK/PD relationships (Aliabadi & Lees, 2001; 
Aliabadi & Lees, 2002). In those studies, however, the effect of the drug was 
measured ex vivo through conventional kill curve experiments in samples of tissue 
cage fluid (TCF) or serum taken at various intervals during treatment.  
 
A model for studies on PK/PD relationships should, ideally, enable a detailed 
description of the pharmacokinetics of the drug, the pharmacodynamic effect on 
bacteria, and preferably also of the host contribution to the measured effects. 
Tissue cage models have the advantage of allowing for repeated sampling, thereby 
permitting close measurement of the drug concentration time profile at the site of 
infection and of antibacterial effect, in presence of the host defence (for a review 
see Clarke, 1989).  
 
Objective 
 
The aim of the studies underlying this thesis was to develop and evaluate a model 
for studies of PK/PD relationships in presence of the host defences. The model 
should allow for close determination of the concentration-time curve of the 
antimicrobial at the site of infection, and of the antibacterial effect. Further, it 
should be possible to study the effect of a range of PK/PD indices. 
  
21 
Comments on materials and methods 
 
Animals 
In study I, crossbred Swedish calves of both sexes were used. The animals were 
purchased through a livestock-marketing organisation and originated from 
different herds. In study II, III and IV, male Swedish Red and White breed calves 
were used. They were acquired from the experimental herd of the Swedish 
University of Agricultural Sciences, where they were born and reared until 
delivery. The animals were fed according to Swedish standards, and water was 
freely available. 
 
Assay of antimicrobial concentrations 
In study I, high pressure liquid chromatography was used to determine 
concentrations of trimethoprim and sulfadoxine in plasma and tissue cage fluid 
(TCF) while in studies II-IV, bioassays based on agar diffusion were used 
(Chapin-Robertsson & Edberg, 1991). To minimise the volume of sample needed, 
a paper disk diffusion assay was used for penicillin in study III. Preliminary 
studies on danofloxacin determination indicated that this approach would result in 
an unsatisfactory detection limit, and a standard cut-well technique was used in 
study II and IV.  
 
In all microbiological drug assays, standards were prepared in pooled uninfected 
TCF sampled prior to the experiments. Large assay trays (225 × 225 mm) were 
used. A series of standards was applied to each tray, and concentrations in samples 
were calculated from the regression equation specific for that tray.  
 
Assay of thymidine concentrations 
In study I, thymidine concentrations in calf serum and TCF were analysed using a 
bioassay described by Nottebrock & Then (1977). This is a variant of the agar well 
method used for drug assay. In brief, an agar medium free from thymidine but 
supplemented with trimethoprim is used and Lactobacillus plantarum ATCC 
8014, susceptible to trimethoprim, is used as test strain. Samples are added to 
wells cut in the agar, and if a sample contains thymidine, trimethoprim will be 
antagonised and the test strain can grow over an area proportional to the thymidine 
concentration. The concentration of thymidine in samples was calculated from a 
log-linear plot of concentration versus zone-diameter of a range of standards.  
 
Bacterial strains, preparation of inoculum and bacterial counts 
The bacterial strains used, Escherichia (E.) coli M17094/83 (study I) and 
Mannheimia (M.) haemolytica serovar A1, Ab 35/85 (study III and IV), were 
isolated from cattle with mastitis and pneumonia, respectively. In both cases, the 
strains were isolated in pure culture and the symptoms described were consistent 
with disease caused by the respective bacterial species. Confirmatory 
identification and serotyping of the M. heaemolytica strain was kindly performed  
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by the French Agency for Food Safety (Agence Française de Sécurité Sanitaire 
des Aliments) in Lyon. 
 
E. coli isolated from bovine mastitis are generally serum-resistant, and this was 
also the case for the strain used in the present experiments. No specific virulence 
factors have (yet) been associated with E. coli from bovine mastitis, and the strain 
used was not further investigated in this respect.  
 
M. haemolytica (previously Pasteurella haemolytica) is a small gram-negative 
rod belonging to the family Pasteurellaceae, i.e. related to the genera 
Actinobacillus, Pasteurella and Haemophilus. It is an important causative agent of 
pneumonia in calves, and the natural infection is characterised by a rapid 
fibrinosuppurative and necrotising response (Ackermann & Brogden, 2000).  
 
In the study with E. coli (I), the inoculum for the tissue cage experiments was 
prepared from a culture in logarithmic growth phase but for the studies with M. 
haemolytica (III and IV) a stationary growth phase culture was used. For in vitro 
studies, use of cultures in logarithmic growth phase is standard as the mode of 
action of some antimicrobial groups, such as the beta-lactams, depend on dividing 
cells for effect. However, the transfer of an in vitro culture to an in vivo setting 
will inevitably induce a lag-phase during which the bacteria adapt to the new 
medium and environment. It was therefore assumed that the difference between 
inoculation with bacteria in logarithmic and stationary growth phase would be at 
most marginal. A procedure similar to that in studies III and IV was also used by 
Clarke (1989b) to infect tissue cages with M. haemolytica.  
 
The effect of the various treatments was monitored over time by use of viable 
counts of bacteria using 10-fold dilutions (I, III, IV). Carry-over of antimicrobial 
from the samples to the culture plates may influence the bacterial counts if the 
concentrations in samples are high enough to inhibit growth of bacteria on the 
plates (NCCLS, 1999). In the present studies, the highest measured concentrations 
of antimicrobial in relation to the MIC of the strain used were in study IV, where 
the maximum concentrations of danofloxacin were around 3 mg/L. The samples 
were first diluted 10-fold, and from this, 0.1 ml was cultured. This means that a 
maximum amount spread over the surface of any agar plate was 0.03 µg. The 
volume of agar in a plate is about 20 ml, and the MIC of danofloxacin for the 
strain of M. haemolytica used was 0.04 mg/L. The maximum concentration in the 
plates would then have been less than 1/10 of the MIC of the strain. Thus, carry-
over was a negligible problem. 
 
In vitro pharmacodynamic studies 
Reproducibility and comparability of MIC and MBC determinations is assured 
through use of standardised media, methods and quality control strains. In study I, 
III and IV, internationally recognised standards were followed where appropriate 
(NCCLS, 1997; NCCLS, 1999).  
 
In study I, results from MIC and MBC determinations as well as killing kinetics 
of trimethoprim and sulfamethoxazole in standard medium (Mueller-Hinton broth) 
were compared with results obtained in broth added with different concentrations  
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of thymidine, bovine serum, or thymidine depleted serum. The purpose of this was 
to screen for the presence of an antagonist that could influence the results in the in 
vivo experiments.  
 
As mentioned in the section on Background, the inherent error of standard two-
fold dilutions for determination of MICs can have a profound influence on the 
calculated PK/PD indices. To overcome this, arithmetic dilution steps were used to 
determine MIC and MBC of penicillin and danofloxacin on M. haemolytica in 
study III and IV. 
 
Tissue cages  
A previously described model with subcutaneously implanted tissue cages 
(Bengtsson, Luthman & Jacobsson, 1984) was employed. The cages were of 
silastic rubber tubing with an internal diameter of 15 mm, perforated at both ends 
but with a non-perforated mid-section. The inner diameter determines the surface-
area where diffusion of antimicrobials can take place and the non-perforated mid-
section will define the volume of the cage lumen.  
 
When this type of cage is implanted subcutaneously, highly vascularised tissue 
grows in and fills the perforated end sections (Bengtsson, 1990). The tissue is 
initially infiltrated with inflammatory cells but with time becomes more collagen 
rich. This is paralleled by a gradual change in composition of tissue cage fluid 
over the first 6 weeks (Bengtsson, Luthman & Jacobsson, 1984). Notably, the 
concentrations of total protein and albumin decrease to approximately 50% of the 
serum levels (Bengtsson, 1990). In the present studies, the experiments were 
performed at 8 to 12 (study I) or 5 to 6 (study II, III and IV) weeks after surgery, 
i.e. at times when it could be assumed that the tissue in each cage was mature and 
the fluid composition was stable.  
 
The tissue cages were injected or sampled through percutaneous puncture with a 
0.6-mm needle and a syringe. To minimise the influence of sampling on 
elimination of drug from the tissue cages, sample volumes were kept to a 
minimum in the small cages used in study III and IV. The large cages in the same 
studies had a volume four times that of the small ones, and sampling was at all 
times kept proportional to the size of the cages. 
 
Tissue cages with membranes 
In study III, tissue cages fitted with semi-permeable membranes were implanted, 
in addition to the standard cages. The intention was to allow for assessment of the 
effects of cellular defences on infection and treatment. By the end of the 
experiments it was obvious that the membranes were often ruptured and 
unfortunately, this part of the experiment had to be dropped. Still, it was decided 
to let the data from membrane cages remain in the data set for further analysis as 
the study aim primarily was to explore its usefulness for studies on PK/PD 
relationships, and not to conclude on some specific issue.  
  
24   
Pharmacokinetics in tissue cages –theoretical considerations 
The distribution of systemically administered antimicrobials into the tissue cage 
model used has been studied previously (Luthman, Bengtsson & Jacobsson, 1984; 
Bengtsson, Luthman & Jacobsson, 1986; Luthman & Jacobsson, 1986; Bengtsson 
et al., 1989; Bengtsson et al., 1991). Irrespective of drug, peak concentrations are 
lower and delayed compared with those in serum, and the rate of elimination is 
slower. This is also a typical feature of other tissue cage models (Bergan & 
Versland, 1978; Carbon et al., 1978; Piercy, 1978; Cars, Henning & Holm, 1981; 
Stanton, Bywater & Palmer, 1982; Ziv, Wanner & Nicolet, 1982; Short et al., 
1987; Clarke et al., 1989a; Walker et al., 1990; Ensink et al., 1996b; McKellar et 
al., 1999). The distribution kinetics differ markedly from that in synovial fluid, 
subcutaneous tissue fluid or granuloma pouch fluid (Bengtsson et al., 1989; 
Bengtsson et al., 1991). Thus, from a pharmacokinetic point of view there is no 
obvious clinical counterpart to this model.  
 
For studies on PK/PD relationships, it is often desirable to include a wide range 
of PK/PD indices. The possibility to obtain such ranges in tissue cages after 
systemic administration of an antimicrobial is limited by the general 
pharmacokinetics of the drug in the animal, by the dose range that can be safely 
administered and by the above described sluggishness of the kinetics in the tissue 
cages.  
 
From a previously elaborated mathematical model linking drug kinetics in serum 
to kinetics in TCF (Bengtsson, Bredberg & Luthman, 1992), it can be inferred that 
transfer of a drug to and from tissue cages follows first-order kinetics and is 
directly proportional to the ratio of the diffusion area (SA) to the volume (V) of 
the cage. It was hypothesised that if a sufficiently small dose of drug is 
administered directly into the tissue cage, diffusion will be from TCF to serum 
only. The elimination of drug from the tissue cages will be a first-order process, 
and the rate of elimination will then depend on the fraction of unbound drug in 
TCF, on the permeability coefficient for drug transfer from TCF to serum and on 
the SA/V ratio. For a given drug, protein binding and permeability will be a 
constant characteristic, and the elimination will be directly proportional to the 
SA/V ratio.  
 
Based on the reasoning and findings above, it was postulated that different 
concentration-time profiles of an antimicrobial can be simulated through injection 
of drug directly into tissue cages with different SA/V ratios (study II). Such a 
procedure would increase the flexibility of the model, making it more suitable for 
PK/PD studies.  
 
General design of tissue cage experiments 
Study I 
A total of 23 calves were used to study the efficacy of trimethoprim and 
sulfadoxine on E. coli (study I). Two tissue cages in each calf were inoculated 
with E. coli. Twenty-four hours after inoculation, the calves were injected iv. with 
different doses of trimethoprim + sulfadoxine (Borgal, 40 mg trimethoprim +  
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200 mg sulfadoxine per ml, Hoechst). First, the label dose (2.5 + 12.5 mg/kg) was 
given as a single injection. The preliminary results indicated that there was no 
observable antibacterial effect, and that concentrations of drug in TCF were below 
MIC. Therefore, in another group of calves, the dose was increased to 5 + 
25mg/kg. Again, no obvious antibacterial effect could be noted. Finally, 7.5 + 37.5 
mg/kg (three times the label dose) was given five times with 12-h interval. In three 
of the calves from this highest dose group, an additional tissue cage on each of the 
three calves was inoculated at 3 h after administration of the first injection of drug 
(i.e. the treatment was prophylactic). Throughout, untreated but infected calves 
were kept as controls. Plasma and TCF was sampled at different times for drug 
assay, and TCF also for viable counts of bacteria. 
 
Study II 
Study II was designed to find out whether different concentration-time profiles 
could be simulated in tissue cages according to the theoretical considerations 
discussed above. Six calves were implanted with cages of the same diameter, i.e. 
the same surface-area, but with differing volumes. The cages were injected with 
penicillin G, enrofloxacin and dihydrostreptomycin in sequence, with a washout 
period in between. Samples were taken for determination of drug concentrations. 
 
Study III 
In study III, the concept from study II was used to develop a PK/PD model. 
Eighteen calves were used for the experiments. In each calf, tissue cages of two 
different volumes but with the same surface area were infected with M. 
haemolytica. Twenty-four h after infection, each tissue cage was injected with 
penicillin G to yield one of three different initial concentrations; 1.1, 2.8 and 5.6 
times the MICtot of the strain used for infection. In addition, one cage in each calf 
was injected with saline and kept as growth control. Only one dose category was 
used in each calf. Injection of drug or saline was repeated either after 24 h, or for 
the lowest and highest dose in the small cages, after 12, 24 and 36 h. Samples 
were taken for determination of drug concentration and bacterial counts. 
 
Study IV 
To further evaluate the model from study III, an antimicrobial with a different 
mode of action, danofloxacin, was chosen. Eight calves were implanted with cages 
of two different sizes and infected with M. haemoltytica, as in study III. Two 
different initial concentrations of danofloxacin were targeted: 13.5 and 27 times 
the MIC of the strain used for infection. One cage of each size in each of the 
calves was injected with each of the doses and one cage of each size was kept 
untreated as control. Injection of drug or saline was repeated after 24 h. Samples 
were taken for drug concentration assay and bacterial counts. 
 
Measures of effect 
In the present studies, various variants of the categories of measures of 
antibacterial effect that were mentioned in the Background were considered and  
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explored. For the final analysis, only maximum reduction of bacterial counts 
(∆cfumax) and the area under the bacterial kill curve (AUBCt) to different times 
were used (I, III, IV).  
 
PK/PD indices 
Protein binding 
Penicillin (study III) 
Previous data indicate that the unbound fraction of penicillin in bovine serum is 
0.5 and the concentration of albumin in bovine serum and TCF is 40 and 20 g/L, 
respectively (Bengtsson, Bredberg & Luthman, 1992). No indications of 
concentration-dependency were noted in that study. Based on these figures, in 
study III the MIC of penicillin against M. haemolytica determined in Mueller-
Hinton broth (reflecting free drug only) was calculated to the total concentration 
of drug needed for inhibition, MICtot, as MICtot = MIC/fu, where fu is the fraction 
of unbound penicillin in TCF. The calculated figure was confirmed though MIC 
determinations in Mueller-Hinton broth added with bovine albumin to a 
concentration of 20 g/L. The MICtot was used for calculation of PK/PD indices 
(see below), and should provide a good estimate of these indices based on free 
concentrations.  
 
Danofloxacin (study IV) 
For danofloxacin (study IV), available information suggested that the free fraction 
of drug in bovine plasma depends on the concentration of the drug in a clinically 
relevant range (Friis, 1993). The method used for penicillin (III) could therefore 
not be applied.  
The free fraction of danofloxacin at different concentrations in bovine serum 
was determined through ultracentrifugation. The results were compared to those 
reported by Friis (1993) using ultrafiltration, and as similar figures were obtained, 
it was assumed that adsorption of drug to the filter membrane is negligible. This 
was also reported for other fluoroquinolones (Okezaki et al., 1989; Zlotos et al., 
1998a). The volume of TCF available was insufficient for ultracentrifugation, and 
ultrafiltration was therefore used to determine the free fraction of danofloxacin in 
TCF. The results were used to calculate the free concentration of drug from the 
measured total concentrations.  
An MICtot for danofloxacin against M. haemolytica was also calculated as 
described for penicillin. 
 
Calculation of PK/PD indices 
Pharmacokinetic parameters were calculated for each calf or tissue cage using 
standard non-compartmental techniques on basis of measured total drug 
concentrations (I-IV).  
 
As the drug is injected directly into the cages the true maximum concentration 
of drug in TCF is C0. However, in study III Cmax was taken as the highest measured 
concentration. In study IV, Cmax was taken as C0 estimated through backward  
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extrapolation of the slope of the concentration-time curve. For further analysis, the 
mean Cmax from the different dosage intervals was used.  
 
The recommended standard measure for PK/PD integration is AUC24 (Mouton 
et al., 2002). Thus, for reasons of comparability the average AUC24, i.e. AUC48/2, 
was used as one of the explored indices.  
 
For penicillin (III) MICtot was used as denominator to estimate AUC/MIC and 
Cmax/MIC based on free drug. For danofloxacin (IV), AUC and Cmax were 
calculated from estimated free concentrations, and indexed with the MIC.  
 
In study I, T>MIC was calculated directly from data. In study III and IV this index 
was estimated assuming first-order kinetics. The model Ct= C0 × e
-Kel×t, where C0 = 
dose/volume, Kel is the elimination rate constant and t is time, was fitted to the 
measured concentrations of penicillin or danofloxacin. From the resulting fit, the 
total time that the concentration exceeded MICtot, or multiples of MICtot, in each 
cage was estimated. The results were compared to corresponding estimates made 
visually from the plots of concentration-time curves. When an estimate based on 
the regression deviated notably from figures calculated directly from these curves, 
it was assumed that the fit of the model was poor and the visual estimate was 
chosen for analysis.  
 
Analysis of data 
To analyse possible differences between groups, analysis of variance with a 
general linear model procedure was used. The main issue assessed was the 
influence of dose and cage-size on t1/2 in the tissue cages (II, III, IV).  
 
In study III and IV, data from different cages on an individual calf are not 
statistically independent. Data were nonetheless pooled for analysis, as the 
primary objective was to assess the usefulness of the model for studies PK/PD 
relationships. To assess whether this influenced outcomes, different procedures 
were used in study III and IV (for details see study III and IV).  
 
The relation between measures of effect and different variants of PK/PD indices 
were first explored though inspection of plots. Data from non-treated cages were 
included with PK/PD indices set to 0. In both studies, the relation between the 
AUBCt to AUCt/MIC group of indices appeared curvilinear. A logarithmic 
transform of AUC/MIC is commonly used in analyses of this type, but for this 
data from the control cages would have to be excluded. As second order 
polynomial models seemed to fit reasonably well, both simple and polynomial 
regressions were fitted to the data sets. The strength of the relations between 
measures of effect and different indices were evaluated by their adjusted 
coefficient of determination (adjusted R
2) and inspection of plots of residuals. Best 
subset regression for effect parameters versus the indices and their quadratic terms 
was used to explore the influence of multiple predictors.  
 
The PK/PD indices that were best correlated with the effect parameter in the 
analyses described above were selected for further analysis through non-linear 
regression with an inhibitory four-parameter Emax model (Holford & Sheiner, 
1981). The fit of the model was assessed by the biological relevance of the  
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estimated constants (i.e. whether they made sense), the confidence intervals, 
inspection of plots observed versus predicted and of residuals.   
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Results and discussion 
 
Infections in tissue cages (I, III, IV) 
Growth of bacteria in non-treated tissue cages 
Immediately after inoculation, the geometric means for bacterial counts in the 
tissue cages were close to the intended concentrations (Table 1). For comparison, 
unpublished data on growth of Streptococcus (S.) dysgalactiae and 
Staphylococcus (S.) aureus in tissue cages are also shown. The counts of M. 
haemolytica (III, IV) increased by more than 3 log cfu/mL over the first 24 h 
(Table 1). Thereafter, the numbers decreased slowly to about 7 log cfu/mL over 
time. Clarke et al. (1989c) observed similar growth patterns for M. haemolytica in 
another subcutaneous tissue cage type in calves. By contrast, for E. coli (I), the 
mean bacterial counts in non-treated cages were almost unchanged to the end of 
the experiment. In individual cages, the counts never exceeded 7 log cfu/mL. This 
is lower than what has been reported for E. coli in tissue cage models in other 
animals (Wagner et al., 1986; Widmer et al., 1991). An apparently limited growth 
rate was also observed for S. dysgalactiae and S. aureus (Table 1).  
 
Table 1. Bacterial counts (log cfu/mL) in non-treated tissue cages infected with 
different bacterial strains (geometric means ± standard deviation) 
 
Bacterial species (study)  No.
1  Sampling time (h)
2 
   -24
3 0  96 
M. haemolytica (III)  28  4.6 ± 0.7  8.1 ±0.3  7.0 ± 0.6 
M. haemolytica (IV)  15  4.6 ± 0.7  7.7 ± 0.6  7.2 ±0.7 
E. coli (I)  11  5.2 ± 0.5  5.8 ± 0.8  5.6 ± 0.6 
S. aureus (unpubl.)
4 5  4.6 ± 0.4  5.1 ± 0.8  6.3 ± 1.6 
S. dysgalactiae (unpubl.)
4 11 4.7 ± 0.5  6.3 ± 0.9  5.4 ± 1.0 
1Number of samples included; 
2  –24 h is immediately after inoculation; 
3  Target 
concentration for inoculation was 4.8 for M. haemolytica and S. aureus and 5.7 for E. 
coli and S. dysgalactiae; 
4 Unpublished data, same type of tissue cages implanted in 
calves of similar age and breed inoculated with S. aureus or S. dysgalactiae. Both 
strains were isolated at the National Veterinary Institute, Uppsala, from bovine mastitis.  
 
In Figure 3, the bacterial counts over the first 24 h for the strains of E. coli and 
M. haemolytica in tissue cages are compared with data from in vitro studies in 
Mueller-Hinton broth and broth supplemented with 40 or 50% heat inactivated 
bovine serum. The generation times of the two strains were estimated from the 
slope of the line between bacterial counts immediately after inoculation and 8 h 
later. For tissue cages, no data were available between these times and it should be 
noted that the estimates therefore include a potential lag-phase. The mean 
generation time of E. coli in tissue cages was negative over the first 8 h (-143 
min), while in broth and broth with serum it was 26 min and 46 min, respectively. 
If the generation time is measured from 4 to 8 h, i.e. without lag-phase, it is similar 
in serum-supplemented broth and in standard broth, as shown in Figure 3.  
 
Growth of E. coli is apparently well supported in 40% serum. As this medium is 
similar to uninfected TCF, the limited growth of E. coli in tissue cages was  
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probably caused by factors other than medium. The in vitro figures were obtained 
from cultures grown aerobically, but in the tissue cages the oxygen tension will be 
reduced. However, as E. coli is facultative in its oxygen requirements, it is more 
likely that other factors, e.g. the host defence, played a role. 
 
Figure 3. Viable counts of bacteria in vitro in Mueller-Hinton (triangles), Mueller-Hinton 
with serum (filled circles) and in vivo in tissue cages (open circles) after different times. 
Data from study I (E. coli), study III (M. haemolytica in tissue cages) and unpublished 
results (M.haemolytica in vitro). 
 
 
For M. haemolytica the generation times in tissue cages, broth and broth with 
serum were 41, 46 and 23 min, respectively. It appears that this species, or strain, 
is well adapted to growth in this environment, and that host factors were initially 
inefficient in limiting the growth.  
 
Host responses 
In study I, the calves reacted to the E. coli infection with a mild to moderate fever 
(39.6 - 40.5 °C). By 24 h after inoculation, swelling around the cages was 
apparent. From the third day post-infection, the body temperatures were 
normalised. Thus, the reaction to the infection was mild.  
 
In a separate unpublished study, the local inflammatory response in tissue cages 
in calves infected with E. coli was monitored through cell counts and 
determination of prostaglandin E2 (PGE2) concentrations (Table 2). Leukocyte 
counts in tissue cage fluid before infection was about 1/10 of that in blood. After 
infection, a numerical increase in mean cell counts could be noted, but the 
response was very variable between calves. The concentration of PGE2 in TCF 
increased markedly after infection. Prostaglandins are released in tissue as a part 
of the inflammatory response, and the observed increases are consistent with those 
reported for experimental infections with M. haemolytica and Streptococcus 
uberis in intraperitoneally implanted dialysis sacs in calves (Thomas, Haddock & 
Lees, 1997). Similar increases of PGE2 in tissue cages in calves have also been 
reported for inflammatory agents such as endotoxin (Luthman et al., 1988) and 
carrageenan (e.g. Landoni, Cunningham & Lees, 1995).  
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Table 2. Bacterial counts, leukocytes and concentration of PGE2 in tissue cage 
fluid after infection with E. coli (means from 6 calves ± standard deviation)
 1 
 
Time
2 (h) Bacterial  counts 
(log cfu/mL) 
Leukocytes 
(×10
9/L ) 
PGE2 
(nmol/L) 
0 4.4   ±0.7  0.6  ±0.3  <0.5  
6 4.0   ±0.8  1.0  ±0.9  8.7  ±11.2 
12 5.2   ±1.3  4.2  ±3.9  85.6  ±122.3 
24 5.3   ±0.8  4.4  ±4.1  112.0  ±115.4 
30 5.8   ±1.2  5.0  ±4.5  156.5  ±104.3 
36 6.1   ±1.0  4.1  ±2.9  189.1  ±128.0 
48 5.9   ±1.1  1.9  ±1.3  144.6  ±116.3 
72 5.9   ±1.2  5.2  ±3.6  110.1  ±116.5 
1 Unpublished data. Infection, sampling and viable counts of bacteria were 
performed as in study I. Leukocytes were counted in a Bürker chamber and 
protstaglandin E2 (PGE2) was measured as described in Luthman et al. (1988); 
2.Inoculated at time = 0 h. 
 
In calves with tissue cages infected with M. haemolytica (III and IV), the 
general signs of infection in terms of fever and haematological changes were more 
pronounced compared with that of calves with E. coli. The swelling around the 
cages was more marked, and the body temperature mostly remained elevated 
throughout the experiments. Clarke et al. (1989c) reported transient mild fever 
when M. haemolytica was used to infect tissue cages in calves. Also, the local 
signs of inflammation were less intense than in the present study, indicating that 
the strain used in the present studies was more virulent.  
 
In study III, efforts were made to follow the concentration of cells in TCF 
(unpublished). An example of cell counts from untreated cages in individual 
calves is shown in Table 3. Cell counts were variable and within 24 h after 
infection, aggregates of cells were often observed. Following infection, many cells 
had a swollen, foamy appearance. These cells did not stain with Trypan blue, 
which indicates that they were still viable. A similar morphology of leukocytes 
exposed to M. haemolytica in tissue cages has been described previously (Clarke, 
Confer & Mosier, 1998), and was ascribed to the membrane damage caused by the 
leukotoxin of M. haemolytica. 
 
Table 3. Examples of total leukocyte counts in tissue cage fluid from individual 
calves after infection with M. haemolytica 
1 
  Leukocytes × 10
9/L (% non viable) 
Time (h)
2  Calf 76  Calf 77  Calf 78  Calf 81 
0  0.53  (19)  0.48  (16)  1.14  (8)  1.90  (7) 
4  0.11  (56)  0.56  (0)  2.24  (14)  1.34  (6) 
10  0.23  (27)  0.67  (7)  0.39  (24)  0.56  (20) 
16  0.04  (29)  0.86  (4)  0.62  (15)  1.09  (21) 
24  0.29  (35)  0.58  (16)  0.75  (36)  0.61  (40) 
28  3.18  (4)  0.71  (1)  1.51  (28)  -  
1 Leukocytes were counted in Bürker chambers after staining with Trypan blue. 
Stained cells were counted as non-viable; 
2 time = 0 h is time of infection. 
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Implications for the model 
The results discussed above show that infections with different bacterial species 
are easily established in the tissue cages. Growth of M. haemolytica in non-treated 
tissue cages was very similar in study III and IV, indicating that the time-course of 
bacterial counts is reproducible. The maximum bacterial counts reached will, 
however, differ between bacterial species. The infections in the tissue cages elicit 
an inflammatory response from the host, as indicated by both systemic and local 
signs. Thus, bacterial growth in the tissue cages is subject to a dynamic response 
from the host, which opens for possibilities to monitor pharmacodynamics of 
antimicrobials in a realistic environment.  
 
The main limitation of the model with respect to infection and host defences is 
that the tissue cage will act as a foreign body (Zimmerli, 1993). In the presence of 
foreign material, host defence mechanisms will be impaired (Zimmerli et al., 
1982; Zimmerli, Lew & Waldvogel, 1984). Further, bacteria can adhere to the 
surface to form biofilms (Cheng, Irwin & Costerton, 1981; Gristina et al., 1987; 
Widmer et al., 1991). This should be borne in mind if comparisons between 
efficacy of different antimicrobial classes are attempted, as the model is likely to 
favour antimicrobials that are able to kill slowly growing bacteria.  
 
Measures of effect (I, III, IV) 
For many infections, bacterial eradication will correlate to clinical success (Dagan 
et al., 2001; Toutain, del Castillo & Bousquet-Mélou, 2002). Eradication will 
reduce the risk for selection and spread of resistance (Dagan et al., 2001), at least 
when only the target pathogen is considered. Thus, direct measures of antibacterial 
effect (i.e. bacterial killing) are likely to predict clinical success. For a discussion 
on advantages and disadvantages of different measures of antibacterial effect, see 
the section Background. 
 
Table 4. Coefficient of variation (%) of measures of bacterial growth for non-
treated tissue cages in study I, III and IV  
Study 
I III  IV 
Effect measure
1 
(No. = 11)  (No. = 28)  (No. = 15) 
∆cfumax  67 58 92 
∆cfu48  224 73  111 
∆cfu96  590 70  112 
      
AUBC0 15  5  9 
AUBC24 10  3  4 
AUBC96 9  6  4 
1 ∆cfumax, maximum difference from t=0 h in bacterial counts; ∆cfu48, ∆cfu96, 
difference in bacterial counts from t=0 to t= 48 and 96 h, respectively; 
AUBC0,  area under the bacterial curve from inoculation, t= - 24h until 
treatment, t = 0 h; AUBC24, AUBC96 = area under the bacterial curve from t = 
0 to t= 24 and 96 h, respectively. 
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In the present studies, bacterial counts were followed over time, resulting in 
individual growth or kill curves for each tissue cage. Initially, different variants of 
the above mentioned categories of measures of effect were explored. In Table 4, 
the coefficients of variation, CV, of some of these measures for non-treated tissue 
cages are shown (data from I, III and IV). The variability of the area measures 
(AUBCt) was much less than that for the point-measures (variants of ∆cfu). This is 
well in line with the findings of MacGowan et al. (MacGowan et al., 2000), who 
studied the within strain reproducibility of different measures of antibacterial 
effect in an in vitro pharmacodynamic model.  
 
In study III and IV the correlation of AUBCt to PK/PD indices was stronger than 
for the point-measures As an example, plots of AUBC96 or ∆cfumax versus 
AUC24m/MIC are shown in Figure 4 (data from IV). A better correlation between 
area measures of effect and PK/PD indices than point-measures was also described 
by Firsov et al. (1997).  
 
 
Figure 4. Examples of correlation between effect parameters and PK/PD indices for 
danofloxacin against M. haemolytica ; plots of ∆ cfumax and AUBC96 versus AUC24/MIC 
(data from study IV). 
 
 
Based on the above, AUBCt  was used as main effect measure for analysis of 
PK/PD relationships. In study III and IV, AUBC48 reflects the total effect during 
treatment. To account for possible effects beyond that time, AUBC96 was also 
used. With that measure, any regrowth before the end of the experiment will be 
included. Similar to IE, the later part of that area will probably be influenced by the 
T>MIC.  
 
Systemic treatment with trimethoprim and sulfadoxine (I) 
Dosage recommendations for parenteral trimethoprim + sulfonamide combinations 
to cattle vary from 2.5 + 12.5 mg/kg bodyweight once daily (label dose in Sweden 
and many other countries) to two, or even three times that dose twice daily 
(Prescott, 2000). The selection of dose for the combination is complicated as for 
cattle, the half-life in plasma is markedly shorter for trimethoprim than for 
currently used sulfonamides (Prescott, 2000).  
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The lowest of the doses above agrees with the findings in a classical dose titration 
study (White, Piercy & Gibbs, 1981), where a dose of 2 + 10 mg/kg of 
trimethoprim + sulfadiazine given iv once daily for five days clearly prevented 
mortality from experimentally induced salmonellosis in week-old calves. 
However, treatment of experimentally induced E. coli mastitis in lactating cows 
with the same drugs dosed 7.5 + 37.5 mg/kg every 12 h four times offered no 
advantage over no treatment (Pyörälä et al., 1994). Data on distribution of 
trimethoprim to milk in healthy udders indicate that, with the doses used, 
concentrations slightly above the MIC of the strain used were maintained for 50-
95 % of the dosage intervals (Kaartinen et al., 1999). Still, mastitis in cattle is 
among the authorised indications for the label dose of these combinations.  
 
Study I was conceived with the above in mind. Tissue cages were infected with 
E. coli and, 24 h later, the calves were treated with different doses of trimethoprim 
+ sulfadoxine iv. No effect of treatment could be observed, even when a dose 
corresponding to three times the label dose was given five times with a 12-h 
interval. In a subset of the calves in this dose-group, an additional tissue cage was 
infected 3 h after initiation of treatment. The AUBC to 48 and 96 h in each of 
these cages from the treated calves was lower than in the corresponding cages 
from non-treated animals, but none of the cages was cleared from the infection.  
 
PK/PD relationships 
The PK/PD index that determines the effect of trimethoprim-sulfonamide 
combinations has not been fully elucidated, but some deductions can be made 
from knowledge on the mode of action. Trimethoprim and sulfonamides inhibit 
the tetrahydrofolate-synthesis pathway of many prokaryotes and some protozoa 
(for a review, see Burman, 1986a). Sulfonamides compete with p-aminobenzoate 
(PABA) for the enzyme dihydropteroase, and trimethoprim competitively inhibits 
dihydrofolate reductase, an enzyme later in the pathway. The bacterial cell 
requires tetrahydrofolates for synthesis of purines and certain amino acids, and a 
block in the pathway leads, amongst other things, to a shortage of thymine. If 
protein synthesis continues, this leads to death of the bacterial cell. This 
bactericidal effect, however, is at best only noted for trimethoprim and for the 
weakly synergistic combination of trimethoprim and sulfonamides (Burman, 
1986b). A paradox effect is often observed, which means that when static 
concentrations approach 10 times the MIC, the cidal effect wanes (Angehrn & 
Then, 1973). Taken together, it is probable that concentrations of trimethoprim 
and sulfonamides must be maintained above MIC for a certain time to produce a 
bactericidal effect. High concentrations do not seem to offer an advantage, rather 
the opposite. In other words, the clinical effect most probably depends on the time 
above MIC.  
 
In the highest dose group in study I, the mean T>MIC (MIC of trimethoprim when 
tested in combination with sulfadoxine) in the tissue cages was 94 to 101 h. This 
figure was calculated from the total concentrations of drug in the tissue cages, i.e. 
including the non-active protein bound fraction. The protein binding of 
trimethoprim in bovine serum is around 57% (FASS VET., 2002). From this, the 
MICtot (total concentration in TCF of drug needed for effect) of trimethoprim for  
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the strain used can be calculated to 0.20 mg/L (calculated as for penicillin, see 
‘Comments on materials and methods’). This is close to twice the MIC of free 
drug, and T>2×MIC (86 to 94 h) therefore serves as a good estimate of the time 
during which active concentrations were maintained. It is unlikely that this time 
was too short for any observable effect to occur.  
 
In vitro, static concentrations of similar magnitude as those maintained during 
this time produced a marked bactericidal effect in standard media (Figure 5). It is 
therefore not probable that a paradox effect due to too high concentrations led to 
loss of the cidal effect of the drug combination in vivo.  
 
 
Figure 5. Effect of 1+20 mg/L of 
trimethoprim+ sulfamethoxazole 
against E. coli in Mueller-Hinton broth 
(triangles),  40 %  bovine serum 
(circles) and 40 % thymidine depleted 
bovine serum (squares). 
 
 
The failure to clear infection from the cages inoculated after initiation of 
treatment can be explained by the poor ability of trimethoprim-sulfonamide 
combinations to kill adherent bacteria, as suggested by Widmer (1991). However, 
this does not fully account for the lack of measurable effect in tissue cages 
infected 24 h before treatment, as at least some reduction of planctonic, i.e. non-
adherent, bacteria would be expected. Thus, explanations for the treatment failure 
must be sought elsewhere.  
 
Antagonistic effect of thymidine 
Exogenous thymidine can be used by many bacterial species to bypass the 
inhibitory effect of trimethoprim (Burman, 1986b). It has long been known that 
the activity of trimethoprim in vitro is inversely correlated to thymidine 
concentrations in the medium (Koch & Burchall, 1971; Dornbusch, 1976). 
Therefore, the effect of trimethoprim - sulfamethoxazole in bovine serum against 
the E. coli strain was compared with the effect in thymidine depleted serum (I). In 
the latter medium, the effect was bactericidal and equal to that in standard 
Mueller-Hinton broth while in normal serum, this bactericidal effect was inhibited 
(Figure 5). This shows that the concentration of thymidine in normal bovine serum 
is high enough to antagonise the effect of trimethoprim. Addition of a 
concentration of 0.08 mg/L of thymidine to Mueller-Hinton broth increased the 
MBC of trimethoprim-sulfamethoxazole for E. coli one dilution step, and 0.25 
completely abolished the cidal effect (I). The concentration of thymidine in serum 
and uninfected TCF from 10 calves ranged from 0.2 to 0.5 and 0.7 to 4.0 mg/L, 
respectively, which is in agreement with previously published data on calf serum 
(Nottebrock & Then, 1977) and bovine exudates and tissues (Indiveri & Hirsh, 
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1992). These concentrations are clearly sufficient to inhibit the activity of 
trimethoprim-sulfonamide combinations, at least in vitro.  
 
Clarke et al. (1989c) studied the effect of trimethoprim + sulfadiazine at a dose 
of 5 + 25 mg/kg body-weight once daily for five days on M. haemolytica in a 
tissue cage model in calves. By 48 h, the bacterial counts in treated cages had 
decreased by about 2 log cfu/mL and at the end of treatment (120 h), they were 
about 4 log cfu/mL lower than the initial values. This pronounced decrease 
seemingly contradicts the hypothesis that thymidine levels in bovine TCF are high 
enough to antagonise the effect of trimethoprim. However, the ability of M. 
haemolytica and E. coli to utilise thymidine as an exogenous source may differ. Of 
greater importance is probably that the growth of M. haemolytica in tissue cages 
differed markedly from that of E. coli, and the response of the calves to the 
infection was more intense (III, IV; see ‘Infection in tissue cages’ above). It is 
therefore likely that host responses contributed to a greater extent to the observed 
effect in the cited study by Clarke et al. (1989c). 
 
Taken together, these findings suggest that trimethoprim was antagonised by 
high thymidine concentrations in TCF which explains why no bactericidal effect 
was observed even when the drug concentrations were above MIC for around 90 
h.  
 
Clinical implications  
The possible implications of extracellular levels of thymidine in tissues and body 
fluids for the clinical efficacy of trimethoprim in man has been the subject of 
debate (for a review see Burman, 1986b). Levels of thymidine in serum and urine 
from healthy humans are low (Nottebrock & Then, 1977), but higher levels have 
occasionally been reported for infected urine (Stokes & Lacey, 1978). Reports on 
thymidine requiring mutants isolated from infected sites provide indirect evidence 
of occasional antagonistic effects in vivo are (eg. Koch & Burchall, 1971; Stokes 
& Lacey, 1978; Platt, Guthrie & Langan, 1983).  
 
Regarding animals, Nottebrock & Then (1977) reported widely differing 
concentrations of thymidine in serum from different species, with cattle, mice and 
rats having by far the highest levels. These authors also showed that infections, 
both bacterial and viral, further increased the levels in experimentally infected 
mice. Then (1993) argued that studies on potency of trimethoprim in mice always 
resulted in high 50% effective doses (ED50), which might be explained by the high 
thymidine levels of that animal species. Indiveri & Hirch (1992) reported high 
levels of thymidine in fluids and exudates from infected sites of various animal 
species, and the authors cautioned against use of trimethoprim - sulfonamide 
combinations for treatment of infections where anaerobic bacteria play a role.  
 
More recently, the issue of in vivo antagonistic effects of thymidine was 
addressed in an elegant series of experiments (Tokunaga et al., 1997). A 
thymidine kinase-deficient mutant, incapable of utilising exogenous thymidine, 
was derived from an E. coli strain with known murine virulence. The mutant and 
the parent strain were used to produce systemic infections in mice, and the effects 
of treatments with trimethoprim and other antimicrobials were compared. The  
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ED50 of trimethoprim was more than 20 times higher for infections with the parent 
strain (capable of using exogenous thymidine) than for the mutant, while no 
differences in doses required for effect were observed for the other antimicrobials 
tested, including sulfamethoxazole. This clearly demonstrates that the activity of 
trimethoprim is inhibited by thymidine in vivo in a manner similar to that observed 
in vitro.  
 
The above highlights the need for caution when extrapolating results from 
studies in one animal species to another, and further support the conclusion that 
the lack of observed effect in study I was related by high levels of thymidine in 
TCF. This suggests that deep-seated purulent infections in cattle (e.g. abscesses) 
are refractory to treatment with trimethoprim - sulfonamides. The influence of the 
naturally high thymidine levels of cattle on the effect of trimethoprim-
sulfonamides when used for other indications remains to be investigated.  
 
Simulation of concentration-time profiles in tissue cages (II-IV) 
Studies on PK/PD relationships often aim to determine the PK/PD index that best 
predicts the effect, and the magnitude of this index needed for a certain outcome. 
The analysis of data depends on regression techniques, and it is desirable that the 
range of PK/PD indices studied is as wide as possible.  
 
In study I, the observed t1/2 for trimethoprim in serum and uninfected TCF was 
1.2  ± 0.3 h and 14.1 ± 4.7 h, respectively. This exemplifies the sluggish 
pharmacokinetics that is typical of tissue cages (see Comments on materials and 
methods). After systemic administration of a drug, the concentration-time curve 
will be flat, and the possibility to vary the PK/PD indices will be limited.  
 
To increase the usefulness of the model for PK/PD studies, a way was sought to 
circumvent this problem. On basis of a theoretical reasoning (see “Comments on 
materials and methods”), it was hypothesised that if tissue cages of different sizes 
are used, and drug is injected directly into these, it would be possible to simulate 
different concentration-time profiles of the drug. This was confirmed in study II, 
where penicillin, enrofloxacin or dihydrostreptomycin were injected into tissue 
cages with different SA/V ratios. As predicted, the elimination rate of the drugs 
from TCF was proportional to the SA/V ratio of the cages. Distinctly different 
concentration-time profiles could be simulated, but the variation in 
pharmacokinetic parameters between individual cages of each cage-size and dose-
group was wide in uninfected (II) as well as infected tissue cages (III, IV). This is 
at least partly explained by different amount of tissue in-growth in the cages, 
which implies that the true SA/V ratio will vary and that each cage is unique. 
Nonetheless, the means of t1/2 differed significantly between the different cage-
sizes, but not between drugs (II) or between different doses of the same drug (III, 
IV).  
 
When fluid is removed through sampling, drug is also removed from the tissue 
cage. This will influence the elimination rate to varying degrees depending on the 
volume of the cage, the sample size and the sampling frequency. For study II, the 
elimination induced by sampling was estimated assuming that the tissue cages fill 
up with fluid after each sampling. The calculated impact on t1/2 was marginal, but  
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for further studies it was decided to keep sample volumes to a minimum and 
proportional to the volume of the cages used. 
 
Figure 6. Mean t1/2 of penicillin from 
small (squares) and large (circles) tissue 
cages following different target initial 
concentrations (C0). Data are from study 
II (2 mg/L; uninfected cages, one dose 
only) and III (0.2. 0.5 and 1 mg/L; 
infected cages, multiple doses, t1/2 
calculated after last dose). Vertical bars 
indicate standard deviation. 
 
 
 
 
 
 
 
Figure 7. Mean t1/2 of danofloxacin 
during first (circles) and second 
(squares) dosage interval in different 
cage-types (L= large; S= small) 
following different target concentrations 
(C0). Data are from study IV. Vertical 
bars indicate standard deviation. 
 
 
 
 
 
 
 
 
Infection may influence vascular supply and other factors that determine the 
elimination rate from the tissue cages (Ryan, 1993). The means of t1/2 for different 
doses of penicillin injected into uninfected (II) or infected (III) tissue cages are 
compared in Figure 6. These means were calculated after a single dose in study II 
and after the last of multiple doses in study III and IV. The t1/2 in infected small 
cages was conspicuously longer than in uninfected cages, but not so for the large 
cages. In study IV, the opposite was noted. The t1/2 of danofloxacin was longer in 
the infected large cages, but not in the small, compared to what was expected for 
uninfected cages based on data for enrofloxacin in study II (Figure 7).  
 
It is probable that in both studies (III, IV) the diffusion area of the tissue cages 
was reduced by tissue damage caused by the infection, resulting in slower 
elimination of drug. However, the influence of an infection on t1/2 is expected to 
affect both cage-sizes similarly. The number of observations for each dose and 
cage-type combination is small, and the standard deviation of t1/2 was wide. It is 
therefore likely that these seemingly conflicting results simply reflect a variation 
around the true means.  
 
To assess whether the infection leads to a gradually decreased elimination rate, 
the t1/2 of danofloxacin during the first and second (last) dosage intervals in study 
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IV were compared (Figure 7). The number of data-points for the first interval was 
insufficient to analyse data within calf, but a repeated measures analysis of 
variance was performed with cage-size and dose as between groups factors, and 
t1/2 as repeated measure.  
 
As previously, there was a significant effect of cage-size, but the difference 
between the t1/2 from the two intervals also approached significance (P = 0.07). 
Post-hoc comparison through plots and Tukey’s HSD for unequal numbers 
indicated that the t1/2 was longer in the second dosage interval in the large cages. 
There was a considerable variance, however, and the results should be interpreted 
with caution.  
 
To summarise, by use of the described approach, it is possible to simulate 
distinctly different concentration-time profiles, but it will not be possible to define, 
nor to repeat, exactly the same profile as in in vitro models. On the other hand, the 
variation leads to a wider range of PK/PD indices, which may be an advantage in 
the analysis. The main limitation of the model in this respect is that, with the type 
of tissue cages used, a t1/2 shorter than around 4 to 6 h cannot be simulated, as 
smaller cages would be difficult to sample. A further limitation is the need to 
minimise sample volume.  
 
PK/PD indices of penicillin and danofloxacin (III, IV) 
Through the concept of simulated concentration-time profiles, an important 
prerequisite for the desired model was met. To explore the potential of this model 
for PK/PD studies, the cages were infected with M. haemolytica and the effect of 
different concentration-time profiles of two antimicrobials for which the PK/PD 
relationships are comparatively well known was studied.  
 
The effect of penicillin (III), a beta-lactam, depends primarily on the time above 
MIC, while that of danofloxacin (IV), a fluoroquinolone, is concentration-
dependent (Frimodt-Moller, 2002). Fluoroquinolones are by far the most studied 
antimicrobials with respect to PK/PD relationships. A more limited number of 
studies relate specifically to veterinary medicine, but among those are some recent 
studies on danofloxacin (Lindencrona, Friis & Aarestrup, 2000; Aliabadi & Lees, 
2001; Sarasola et al., 2002). For both drugs, treatment of pneumonia in cattle 
caused by M. haemolytica is among the authorised indications in Sweden (FASS 
VET., 2002) and other countries (Prescott, Baggot & Walker, 2000).  
 
Free concentrations of drug 
The clinical relevance of protein binding is an ever-debated topic. As mentioned in 
‘Background’, only the free fraction is active against bacteria (Rolinson, 1980). 
Further, the free concentration in serum is a reasonable surrogate marker for the 
free concentrations at the site of infection (Cars, 1997). Thus, the recommendation 
that PK/PD indices should be calculated from the free concentration of the drug 
(Mouton et al., 2002) is well founded. For this, different approaches were used in 
study III and IV, as explained in ‘Comments on materials and methods’. 
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Penicillin (study III) 
The MIC of penicillin for M. haemolytica determined in standard media was 0.12 
mg/L. The total concentration of penicillin needed in TCF to yield a free 
concentration equal to that, MICtot, was calculated to 0.18 mg/L, and this was also 
confirmed by in vitro determinations in protein enriched media. This MICtot was 
then used to calculate the PK/PD indices.  
 
Danofloxacin (study IV) 
The protein binding of danofloxacin in serum was concentration dependent in the 
range from 0.08 to 0.31 mg/L with a maximum binding of 57% at very low 
concentrations and 30% at the higher concentration of drug. Above the latter 
concentration, the fraction bound seemed to be constant (Figure 8). This concurs 
with the findings of Friis (1993).  
 
Figure 8. Protein bound fraction of 
danofloxacin as a function of drug 
concentration in serum (open squares, 
broken line) TCF (filled circles, solid 
line), and TCF calculated from data for 
serum (filled triangles). The linear fit to 
data reported for serum by Friis (1991) 
is shown as dotted line. 
 
 
 
 
 
It has been suggested that quinolones, as most drugs, bind primarily to albumin 
(Okezaki et al., 1989; Zlotos et al., 1998a; Zlotos et al., 1998b). In above cited 
study by Friis (1993), protein binding in bronchial secretions was around 30% 
irrespective of drug concentration. In these secretions, the drug concentrations 
were similar but the albumin concentration higher than in plasma. This indicates 
that in addition to albumin, danofloxacin binds to at least one other molecule in 
bovine serum (Friis, 1993). Interestingly, protein binding of danofloxacin in goat 
serum does not seem to be concentration dependent (Atef et al., 2001).  
 
A similar concentration dependency was found also for binding of danofloxacin 
in TCF. The difference in percentage bound at the respective drug concentrations 
is fully explained by the difference in protein concentration between serum and 
TCF (Figure 8). Thus, whatever the molecular background to the observed 
concentration dependency, the conditions are probably similar in serum and TCF. 
Visual inspection of a plot of data indicated that a linear approximation of the 
bound fraction versus concentrations from 0.08 and 0.31 mg/L would yield 
reasonable estimates within that range. Further, it was assumed that above 0.4 
mg/L of drug, the fraction of protein bound drug in TCF would be constant (10%).  
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The procedure with a linear approximation will slightly overestimate the protein 
bound fraction at concentrations close to the saturation level, but as binding at 
those levels is below 20%, this was considered negligible. Of greater importance is 
probably that the approximation is valid for uninfected TCF. Following infection, 
the protein content will increase, and other changes in the chemical composition of 
TCF, such as a decrease in pH, will take place (Clarke et al., 1989c). This means 
that the true free concentration of drug may differ from the estimates.  
 
Simulated PK/PD indices 
As mentioned in “Background”, PK/PD indices are mostly correlated with 
efficacy through use of various regression techniques. A commonly encountered 
problem is co-linearity, or interdependency, of the indices. In animal models, this 
interdependency can be reduced by varying dose and dosing interval, and by use 
of strains with different MICs (Vogelman et al., 1988).  
 
Table 5. Correlation between selected PK/PD indices in treated cages 
in study III and IV (Pearson’s coefficient of correlation, r)
 1 
   C max/MIC AUC24m/MIC 
Study III  AUC24m/MIC 0.88  - 
 T 96>MIC 0.80  0.93 
      
Study IV  AUC24m/MIC 0.78  - 
 T 96>MIC 0.29  0.72 
1 All coefficients of correlation except Cmax/MIC to T96>MIC in study IV 
were significant (P < 0.05).  
 
In study III, the correlation between all PK/PD indices in treated cages was 
significant (Table 5). As an example, a plot of AUC24m/MIC versus T96>MIC is 
shown in Figure 9. The chosen study design was not optimal to separate the 
indices. For two of the doses, the dosage interval was 12 h in the tissue cages with 
shorter t1/2 and 24 h in those with longer t1/2. The more frequent dosing in cages 
with more rapid elimination compensates the fact that a single dose of a certain 
magnitude leads to smaller AUC/MIC and shorter T>MIC in these cages, compared 
with those with longer t1/2. This was most pronounced in the cages given the target 
Cmax/MIC of 1.1, where the AUC24m/MIC was 22 ± 5 h in the cages with shorter 
t1/2, compared with 21 ± 8 h in cages with longer t1/2. For the medium dose (target 
Cmax/MIC of 2.8), where all cages were dosed every 24 h, the corresponding 
figures were 20 ± 6 h and 46 ± 20 h, respectively.  
 
The correlation between indices was less pronounced in study IV, where 
danofloxacin was dosed twice with 24 h interval in both cage-types (Table 5 and 
Figure 9). Still, all coefficients of correlation except that for Cmax/MIC to T96>MIC 
were significant. The figures are comparable with those reported by Vogelman et 
al. (1988) in the first study that successfully minimised the interdependency of the 
PK/PD indices in an animal model. They reported coefficients of determination, 
R
2, for T>MIC to the other indices of 0-46% (8 and 52% in study IV), and 39-87% 
for AUC to Cmax (61% in study IV).  
 
Another factor of importance in analysis of outcomes is the range of the PK/PD 
indices. In study I, the ratio between 10
th and 90
th percentile were 6, 7 and 11 for  
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Cmax/MIC, AUC24m/MIC and T96>MIC, respectively. For study IV, the 
corresponding figures were 7, 16 and 6. In the subsequent analyses, data from 
untreated cages where the PK/PD indices = 0 were also included which means that 
the total range studied was wider.  
 
 
Figure 9. Correlation between AUC24m/MIC and T96>MIC in study III (penicillin; left panel) 
and study IV (danofloxacin, right panel). 
 
This shows that the model allows for simulation of a wide range of PK/PD 
indices, and that the interdependency of the indices can be reduced provided that 
doses and dosage intervals are carefully chosen. 
 
PK/PD relationships of penicillin and danofloxacin (III, IV) 
Influence of dose and cage-type on effect 
In study III and IV the variance of PK/PD indices within each category (group) of 
dose and cage-type was wide and data were not further analysed on this basis. 
Nonetheless, to illustrate the influence of dose, cage-type and the interaction 
between these factors on the effect parameter AUBC96, analysis of variance was 
performed on the two data sets. For this analysis, the membrane cages were 
excluded from study III.  
 
In Figure 10, plots of the least square means of AUBC96 for the different dose 
categories per cage-type are shown. For data from study III (penicillin), only the 
effect of dose was significant. The lack of influence of cage-type is explained by 
the fact that the PK/PD indices did not differ markedly between some of the 
categories, for reasons discussed above. In contrast, for study IV (danofloxacin) 
no difference was observed between the control cages, but treatment led to a more 
marked effect in the cages with longer t1/2 than in those with shorter t1/2 in both 
dose-groups.  
 
The analysis above confirms that the simulated concentration-time profiles lead 
to different degrees of effect. It is, however, only an indirect way to compare the 
effect of different PK/PD indices defined by dose, dosage-interval and cage-type 
(i.e. rate of elimination). 
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Figure 10. Least square means of AUBC96 of M. haemolytica for different dose categories 
(target Cmax/MIC) in study III (penicillin; left panel) and IV (danofloxacin; right panel) in 
small (squares) and large (circles) tissue cages. Bars indicate 95% confidence interval.
 
Predictive PK/PD index  
Regression techniques were used to explore data, and to define the PK/PD index 
that best explained the effect (III, IV). A curvilinear pattern revealed in plots of 
AUC/MIC to AUBCt  was dealt with through use of second order polynomial 
regression. Polynomials are linear in their parameters, and can therefore be 
compared to simple linear regressions. To account for the difference in number of 
variables, adjusted R
2 was used for comparisons. As can be seen in Figure 11, the 
fitted polynomial line is quite close to that of the Emax model.  
 
Penicillin (III) 
In the study on penicillin (III), initial exploration of data using simple and 
polynomial regression indicated that Cmax/MICtot was not a good predictor of the 
effect measured as AUBC96. For the remaining indices, AUCt/MIC, T96>MICtot, and 
T96>0.25×MICtot, adjusted R
2 of the best models ranged from 0.52 to 0.58 with the 
highest figures for AUCt/MICtot. The fit of the Emax model was adequate for 
AUBC96 versus AUC24m/MICtot or AUC96/MICtot (Figure 11). The fit to T>0.25×MICtot 
also yielded reasonable estimates but the confidence interval for the Hill slope 
constant was wide. For T96>MICtot, the fit was considered inferior, as the estimate of 
maximum effect (the bottom of the curve in an inhibitory model) was poor. The 
scatter of data was pronounced for all variables over the whole range, and the co-
linearity of the predictors strong. Nonetheless, the analysis slightly favours 
AUCt/MICtot as predictor of effect of penicillin on M. haemolytica.  
 
For beta-lactam antibiotics, a clear correlation between the time above MIC and 
effect has been demonstrated in various models (Cars, 1997). This is also 
supported by clinical evidence (for a review see Turnidge, 1998). However, 
Lavoie and Bergeron (1985) showed a better correlation between bacterial killing 
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and the ratio of AUC in serum and clots than with T>MIC in a fibrin clot model in 
rabbits. The authors suggested that a large gradient is needed to penetrate into the 
core of the clot, where bacteria might otherwise be protected. It is possible that 
such penetration barriers also played a role in study III.  
 
Figure 11. Penicillin against M. 
haemolytica (study III): relationship 
between AUBC96 and PK/PD indices. 
Low dose is indicated with filled circles, 
open circles are all other doses and non-
treated cages. Fits of polynomial 
regressions (dotted line) and of an Emax 
model to all data-points (solid line), and of 
an Emax model to data excluding low dose 
cages are shown.  
 
The bactericidal effect of penicillin is slow, and increased killing with 
increasing concentrations is only reported for concentrations up to about four 
times the MIC (Vogelman & Craig, 1986; Li, Nix & Schentag, 1994). This 
concentration-dependency at levels close to the MIC offers another explanation to 
the findings in study III. In treated cages, the Cmax/MIC ranged from 1.1 to 12.9, 
with a median of 1.9. Thus, in most cases the concentrations were in the range 
where a certain concentration-dependency would be expected. The T96>2×MICtot did 
not seem to correlate well with AUBC96, but T96>0.25×MICtot did, so it is probable that 
the overall effect was influenced by concentrations below MIC.  
 
Löwdin et al. (Löwdin et al., 1996) studied PME in an in vitro dynamic model. 
They showed that the PME of penicillin on Streptococcus pyogenes was longest in 
experiments where the t1/2 was shortest, while for longer t1/2 the effect was less 
pronounced. The authors hypothesised that when concentrations decline slowly, 
the penicillin binding proteins are not fully saturated when the drug concentration 
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approaches MIC, and growth can resume earlier. Similar findings regarding 
correlation between PME and t1/2 have also been reported for aminoglycosides 
(den Hollander et al., 1998a). 
 
 
Figure 12. Penicillin against M. 
haemolytica (study III): 
relationship between AUBC96 
versus T96>0.25 × MIC  in small cages 
with rapid elimination rate (filled 
squares) and large cages with 
longer elimination rate (open 
squares).  
 
 
In study III, the effect of a given T96>0.25×MICtot was slightly more pronounced in 
the small cages with shorter t1/2 than in the large cages (Figure 12), which indicates 
a similar phenomenon.  
 
According to the above, it is possible that in study III the PK/PD indices and 
pharmacokinetic parameters interacted in their influence on effect. If so, this could 
in part explain the scattered appearance of data in plots. This would be most 
pronounced for the dose group with a target Cmax/MIC close to MIC. Re-
examination of data revealed that the treated tissue cages in the lowest target 
Cmax/MIC, all had a T96>MIC below 50 h and T96>0.25×MIC above that value. After 
exclusion of this dose group, the fit of the Emax model to T96>MIC was improved, but 
the confidence interval of the Hill slope was still wide. For the remaining indices, 
the fits were similar to those to the complete data set (Figure 11).  
 
Danofloxacin (IV) 
Like in study III, initial exploration of data in study IV (danofloxacin) indicated 
that Cmax/MIC was not a good predictor of either AUBC48 or AUBC96.  The 
AUC96/MIC and AUC24m/MIC were equally good predictors of AUBC48 (adjusted 
R
2 of 0.89 for both regressions) while for prediction of AUBC96, AUC96/MIC was 
somewhat better than AUC24m/MIC (adjusted R
2 of 0.87 and 0.81, respectively). 
As AUC96/MIC reflects the drug exposure both during and beyond the treatment 
intervals, it is logical that this index is a better predictor of the effect measure that 
includes the re-growth phase. The T96>MICtot was inferior to both AUC96/MIC and 
AUC24m/MIC for prediction of AUBC48 (R
2 = 0.81) but equal to AUC24m/MIC for 
AUBC96 (R
2=0.78). Adequate fits of the Emax model were obtained for both 
AUCt/MIC indices related to AUBC48 (Figure 13), and to AUBC96.. For the other 
indices, the fit of the Emax model was clearly inferior. Taken together, the analyses 
indicate that AUCt/MIC was the group of indices that correlated best with the 
effect of danofloxacin against M. haemolytica in the tissue cages.  
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Figure 13. Danofloxacin 
against M. haemolytica. Fit of a 
four –parameter inhibitory Emax 
model to AUBC48  versus. 
AUC24m/MIC (data from study 
IV). 
 
 
The PK/PD relationships of fluoroquinolones have been studied extensively. 
The effect is concentration-dependent. In in vitro and in vivo models, AUC/MIC 
(e.g. Madaras-Kelly et al., 1996; Bowker et al., 1999; Andes & Craig, 2002b) or 
Cmax/MIC (e.g. Blaser et al., 1987), or both (e.g. Drusano et al., 1993; MacGowan 
et al., 2001), have been identified as the most important indicators of efficacy.  
 
Hence, in this respect the findings in study IV are consistent with those of 
others. Results from studies where models with tissue cages or abscesses were 
used to study the relative importance of the different PK/PD indices of 
fluoroquinolones are, however, somewhat more contradictory. In a tissue cage 
model in guinea pigs designed to mimic device related infections, none of the 
PK/PD indices were correlated with reduction of bacterial counts over 48 h 
(Blaser et al., 1995). Xuan et al. (2001), reported a good correlation of both 
AUC/MIC and Cmax/MIC to bacterial killing in a rabbit tissue cage model. In a 
model with some resemblance to tissue cages, i.e. established subcutaneous 
abscesses in mice, Cmax was more predictive for effect than AUC (Sterne et al., 
2001). 
 
It is possible that these seemingly conflicting results are explained by 
differences in study design. It was suggested by Drusano et al. (1993) that 
Cmax/MIC is the best predictor of effect when this index is above 10, while below 
that value AUC/MIC is more important. According to this, the proportion of data 
with values of Cmax/MIC below 10 could influence the conclusions of a specific 
study. Further, in a study on the effect of gemifloxacin on Streptococcus 
pneumoniae, MacGowan et al (2001) showed that the rate of kill, measured as 
time to a 99.9% decrease in bacterial counts, was best predicted by Cmax/MIC, 
while AUC/MIC was predictive of the overall effect measured as AUBC. This 
illustrates how the choice of effect parameters may affect the results, as they 
measure different events that may relate differently to the PK/PD indices.  
 
Magnitude of the predictive index 
For drug dosage prediction, not only the PK/PD index that determines the effect 
but also its magnitude must be identified. In study III, the results concerning the 
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best predictive index were ambiguous which precludes further estimations. 
Therefore, in the following only results from study IV and other findings for 
fluoroquinolones will be discussed.  
 
In experimental as well as in clinical studies, the estimate of the magnitude of 
the PK/PD index needed for effect will depend on, amongst other things, the 
chosen endpoint. This is illustrated by data reported by Forrest et al. (1993). In a 
retrospective study on nosocomial pneumonia treated with ciprofloxacin, the 
probability of treatment success was high for patients where AUC/MIC was above 
125 h. However, bacterial eradication was more rapid when the AUC/MIC was 
above 250 h than when this figure was 125 to 250 h. Figures of the same order of 
magnitude for rapid bacterial eradication have also been reported for other 
fluoroquinolones from other clinical studies (Forrest et al., 1997; Preston et al., 
1998; Highet et al., 1999; Meinl et al., 2000; Tran et al., 2000). It has been 
suggested that to reduce the emergence and spread of resistant bacteria, 
antimicrobial therapy should optimise the potential for bacterial eradication in 
human respiratory tract infections (Dagan et al., 2001). That concept is probably 
valid for other types of infections in man as well as in animals. Hence, toxicology 
permitting, the higher level (250 h) in the study by Forrest et al. (1993) may be 
closer to the optimal target of AUC/MIC than 125 h, which is a commonly cited 
figure that rather represents the minimum.  
 
In study IV, the level of AUC24m/MIC that produced 80% of the response 
measured as AUBC48 was 244 h which is in line with these higher figures. Similar 
levels for 80% or near maximal response have been reported in studies on 
different fluoroquinolones on various bacterial species in in vitro dynamic models 
(Madaras-Kelly et al., 1996; MacGowan et al., 1999b; MacGowan, Wootton & 
Holt, 1999) and in animal models (Andes & Craig, 1998; Bédos et al., 1998; 
Andes & Craig, 2002b). For studies using tissue cages to contain an infection 
(Fernandez et al., 1999; Xuan et al., 2001), an AUC/MIC in TCF producing near 
maximum bacterial killing can be estimated to above 150 h.  
 
Lower figures (35-65 h) are reported in some studies for S. pneumoniae (Lacy et 
al., 1999; Lister & Sanders, 1999; Hershberger & Rybak, 2000; Zhanel et al., 
2001) but not in others (Bédos et al., 1998; MacGowan et al., 1999a; MacGowan 
et al., 2001). It is probable that the conflicting data reflect differences in study 
design.  
 
This may also explain the lower figures found in studies relating specifically to 
danofloxacin. Lindencrona, Friis & Aarestrup (2000) reported on the effect of 
danofloxacin on Salmonella Typhimurium in an in vitro dynamic model and from 
presented data, an AUC/MIC of 80 h producing 80% response can be estimated. 
Aliabadi & Lees (2001) studied the killing kinetics of danofloxacin on M. 
haemolytica in vitro in TCF from goats sampled at various times during treatment. 
The AUC/MIC at the concentrations obtained in the samples (i.e. static 
concentrations) were calculated, and for elimination of bacteria 52-59 h was 
needed. The pharmacodynamics of danofloxacin against M. haemolytica has also 
been studied in a model of calf pneumonia (Sarasola et al., 2002). Although no 
dose-titration was made, it can be noted that a bolus dose giving an AUC0-∝/MIC 
of 43 h was sufficient to prevent development of pneumonia.   
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In conclusion, the observations on PK/PD relationships of penicillin (III) were 
unclear, which could partly be explained by an interaction of PK/PD indices and 
pharmacokinetic parameters. For danofloxacin (IV), the results concur with 
reports for other fluoroquinolone – bacterial species combinations from 
experimental models and clinical studies in man.  
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Concluding remarks 
 
The understanding of PK/PD relationships of antimicrobials, and implications 
thereof for dose setting, has increased considerably over the last decades. Most of 
the research has been focused on human medicine. It is probable that the general 
results are applicable also to the major animal species in veterinary medicine 
because the target for antimicrobial drugs is the bacterium, not the host. The 
antimicrobial-pathogen combinations of interest, however, differ between animal 
species. Clearly, veterinary medicine would benefit from an expansion of this area.  
 
In the studies underlying this thesis, a tissue cage model in calves was adapted 
for studies of PK/PD relationships of antimicrobials. The advantage of tissue 
cages is that repeated sampling can be performed. Thereby, both concentrations of 
drug at the site of infection and the antibacterial effect can be monitored in 
presence of the host defences. Through use of tissue cages with different SA/V 
ratios, and injection of different doses of drug directly into the cages, a range of 
concentration-time profiles can be simulated. By use of this concept, the effects of 
a range of PK/PD indices of penicillin and danofloxacin could be studied. The 
validity of the developed model needs to be challenged by direct comparison with 
other models, and by clinical trials in relevant animal species.  
 
So far, the results suggest the here described model can be a useful intermediary 
step between in vitro studies and more elaborate infection models in relevant 
animal species. Through use of different experimental models in sequence, factors 
of relevance for antimicrobial effect can be identified, and the magnitude of the 
relevant PK/PD index needed for effect can be estimated. Together with data on 
population pharmacokinetics and distribution of MICs of relevant target 
pathogens, this information can be used to select doses and dosage regimens for 
clinical trials.  
 
A reduction of unnecessary use of antimicrobials is a natural component of 
strategies aiming to contain resistance. However, it is probable that the 
epidemiology of resistance is influenced not only by how often, but also by how 
we use these drugs. Evidence that the dose and dosage regimen of an antimicrobial 
influence the risk for emergence of resistant mutants of the target bacterium is 
accumulating. Hitherto, corresponding information regarding the risk for selection 
and transfer of resistance genes is lacking. Nevertheless, it is plausible that factors 
such as the route of administration, dose and treatment time play a role. The 
described model could be an interesting option for studies on the influence of host 
defences on the pharmacodynamics of resistance. The increase in resistance to 
antimicrobials among bacteria from man and animals is a threat to successful 
therapy of bacterial infections. Therefore, an understanding of the relation 
between PK/PD and the risk for emergence of resistance is probably the most 
urgent research need in this area.  
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